Disease relevance of IGJ

• Expression of the recombinant human immunoglobulin J chain in Escherichia coli [1].
• Systolic hypertension; alpha blockers and prostatism; are beta blockers still indicated; diabetes, obesity, and hypertension -- comments on the JCH contents [2].

High impact information on IGJ

• These results establish an important role for PU.1 in the regulation of immunoglobulin J-chain gene expression and provide new insights into the function(s) of the Ets transcription factors in lymphoid cells [3].
• A stage-specific enhancer of immunoglobulin J chain gene is induced by interleukin-2 in a presecretor B cell stage [4].
• During a primary immune response, murine B lymphocytes are induced to express the gene for the immunoglobulin J chain [5].
• The relative preferences for modifications of all possible sites defined by a base pair step (e.g. GC) were determined within all quartet contexts such as (IGCJ) [6].
• By ISH, the immunoglobulin J chain, and the kappa and lambda light chain were rarely expressed in the H & RS cells, however, no T-cell markers could be detected [7].

Chemical compound and disease context of IGJ

• Obesity and hypertension in children; caffeine, stress, and elevated blood pressure; resistant hypertension; and is it lowering of blood pressure alone that accounts for reduction in cardiovascular events? Comments on the JCH Contents [8].

Associations of IGJ with chemical compounds

• METHODS: Cocktails of synthetic deoxyoligonucleotides coding for immunoglobulin J chain and kappa light chain were 3' end labelled enzymatically with digoxigenin using terminal deoxynucleotidyl transferase [9].

Physical interactions of IGJ

• 1. The NF beta A binding element shares 100% sequence identity with a novel PU.1 binding element recently found in the immunoglobulin J-chain promoter [10].

Other interactions of IGJ

• Some new proteins, not shown before in 2-DE patterns of NLF were also found, e.g. mammaglobin B, (2)-microglobulin and immunoglobulin J chain [11].

Analytical, diagnostic and therapeutic context of IGJ

• Image-guided gastrojejunal feeding tube placement patients required gastrostomy at an average age of 23.8 months, with conversion to IGJ an average of 17.2 months later [12].
• Although image-guided gastrojejunal feeding tube placement (IGJ) is becoming the access of choice in many centers, few studies have compared long-term results with surgical jejunostomy (SJ) [12].

References